tumors that invade the lamina propria, but not the muscularis propria, and carry a high likelihood of progression (30 -50%). 2, 3 Although most recurrent superficial tumors are not life-threatening, they require frequent surveillance, and a significant number of patients also may need additional treatment, such as endoscopic resection and intravesical chemotherapy installation. Conversely, a small number of superficial tumors are life-threatening; these need to be detected early, so that adequate aggressive therapy may be instituted. 4, 5 In this context, identifying and developing a marker capable of predicting tumor behavior is of great importance. Although a large number of markers, such as oncogenes, tumor suppressor genes, growth factor receptors, adhesion molecules, and cell proliferation markers, have been evaluated extensively as potential prognostic factors in patients with bladder carcinoma, 6 -9 tumor grade and stage still are considered the most significant variables for predicting patient outcome.
The transmembrane-4 superfamily (TM4SF) is a surface glycoprotein family that is involved in cell growth, adhesion, and motility. It is comprised of 20 known members with 20 -30% sequence similarity, five of among which (motility-related protein 1 [MRP1/CD9], ME491/CD63, KAI1/CD82, CD151, and CD81] may be implicated in cell migration, proliferation, and tumor cell metastasis. 10, 11 TM4SF has a basic structure of four hydrophobic transmembrane domains (TM1-TM4), two extracellular loops bearing the site of gylcosylation, and short cytoplasmic N and C termini. 12 The motility-related protein/CD9 is located on chromosome 12 (12p13) and is distributed widely among all cell types. To date, CD9 is the best characterized of the TM4SF members. It is capable of interacting with other transmembrane proteins, such as integrins and other tetraspanins, to form a complex that facilitates cell adhesion, motility, and signaling. 13, 14 CD9 has an important role in inhibiting cell motility in numerous neoplastic cell lines, including lung, gastric, pancreatic, and bladder carcinomas. 11, 15 Clinical studies have shown the important prognostic value of CD9 in adenocarcinoma of the lung, colon, breast, pancreatic, and in squamous cell carcinoma of the esophagus and the oral cavity. 16 -22 However, because the value of CD9 protein as a prognostic factor for urothelial bladder carcinoma has not been examined to date, we attempted to define its value in the current study. First, we examined the relation between CD9 expression and the two most significant established prognostic factors, grade and stage, in urothelial bladder carcinoma. In a second step, we examined the potential value of CD9 in predicting tumor recurrence and tumor progression in patients with pTa and pT1 disease.
MATERIALS AND METHODS

Patient Population
A retrospective, consecutive study covering an 11-year period (1988 -1999) was conducted. Patients with a prior diagnosis of bladder carcinoma with or without treatment were excluded from the study. Pathologic material included transurethral resection specimens from bladder tumors. For every patient, hematoxylin and eosin stained slides were reviewed by one pathologist (P.M.), and the histologic grade and stage were reassessed. The 1973 World Health Organization grading system was used for histologic assessment, and the sixth edition of the TNM classification system was used for staging disease. 23, 24 Follow-up data were retrieved from our archives and from the medical records. The closing date for the study was the date of the patient's last histologic diagnosis, cystectomy, or death with autopsy performed. Treatment consisted of endoscopic resection for superficial tumors (pTa and pT1) and intravesical bacillus Calmette-Guerin (BCG) for patients with high-risk tumors, such as high-grade lesions, and frequent recurrences. Depending on follow-up, tumors were stratified into four subgroups: 1) a tumor regression subgroup (from pTa to no detectable tumor and from pT1 to no detectable tumor or to pTa); 2) a tumor recurrence subgroup (from pTa to pTa and from pT1 to pT1); 3) a tumor progression subgroup (from pTa to Ն pT1 and from pT1 to Ն pT2); and 4) a subgroup of tumors with no follow-up. To address the first issue of the study, i.e., the relation between CD9 expression and tumor stage and grade, pT2 tumors were included in the analysis as well as pTa and pT1 tumors. To address the second issue of the study, i.e., the relation of CD9 immunoexpression with both tumor recurrence and tumor progression in patients with SPTs of the bladder, only pTa and pT1 tumors were included in the analysis.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on paraffin embedded tissues. Tissue sections were deparaffinized with xylene and washed with ethanol. For immunostaining enhancement, sections were pretreated in a microwave oven in 0.01 M citrate buffer, pH 6.0, at 98°C for 30 minutes. Sections were incubated with a monoclonal anti-CD9 antibody (Novacastra, Newcastle, U.K.) diluted at 1:20. Endogenous peroxidase was blocked with 0.3% hydrogen peroxidase for 5 minutes. Thus, sections were incubated with mouse Envision horseradish peroxidase for 30 minutes. IHC was performed using the automated stainer, Dako Au-tostainer (Dakopatts, Copenhagen, Denmark). These incubations were performed at room temperature, and sections were washed in Tris buffered saline between incubations. Diaminobenzidine complex was used as the chromogen. Tissue sections from patients with fibroadenoma were used as positive controls. Staining of normal bladder mucosa with anti-CD9 showed strong membranous positivity of the urothelium (Fig. 1) . In negative controls, a normal goat serum was used in place of the primary antibody, resulting in a lack of detectable staining.
IHC for CD9 staining was performed on the first resection material only; therefore, subsequent biopsies were not stained. Evaluation of the IHC was done twice by 1 pathologist (P. M.) with a 1-month interval. All of the tissue on the slide was scanned for CD9 expression, and the average expression was calculated for the entire slide. Samples for CD9 expression were stratified into three categories, depending on the percentage of CD9 positive cells, as described previously. 21 Samples with Ͼ 50% CD9 positive tumor cells were categorized with positive CD9 expression, samples with 5-50% stained tumor cells were categorized with reduced CD9 expression, and samples with Ͼ 5% stained tumor cells were categorized with negative CD9 expression.
Statistical Analysis
For statistical analysis, the following baseline variables were considered for their prognostic value: age at presentation, gender, tumor stage, tumor grade, and CD9 expression (considered as a categoric variable). Associations between variables were studied using the chisquare test or the Fisher exact test, as appropriate. The date of diagnosis was considered the time of origin. For recurrence free and progression free intervals, we considered the first recurrence and the first progression, respectively, as events. Multivariate logistic regression models were defined to predict the occurrence of the first progression or the first recurrence while adjusting for all the baseline variables. Recurrence free and progression free survival curves were computed using the Kaplan-Meier method. For comparison between curves, we used the log-rank test.
Multivariate analyses based on a Cox proportional hazards model were used to identify the most significant factors related to outcome. The results of the multivariate analyses are expressed in terms of either odds ratios or hazard ratios, which were derived from the estimated regression coefficients along with their 95% confidence intervals (95% CI). P values Յ 0.05 were considered statistically significant. All analysis were performed with the Stata statistical software package (version 7.0; Stata Corporation, College Station, TX).
RESULTS
Three hundred twenty patients met our inclusion criteria. Clinical data, grade, and pathologic stage are summarized in Table 1 . Of 320 tumors, 118 tumors were classified as pTa, 111 tumors were classified as pT1, and 91 tumors were classified as pT2 at initial diagnosis. Eighty-five tumors were well differentiated (Grade 1), 122 tumors were moderately differentiated (Grade 2), and 113 tumors were poorly differentiated (Grade 3). The age of patients ranged from 27 years to 98 years (mean, 70.4 years). There were 257 males and 63 females, with a male-to-female ratio of 4:1. The follow-up period ranged from 12 months to 240 months (median, 30 months; mean, 43.6 months). For 202 patients, the follow-up period was Ն 12 months. Shorter follow-up periods of 2 months, 3 months, and 6 months were noted in 3 patients (1 patient each with pTa, 1 pT1, and 1 pT2 tumors, respectively) because they underwent a cystectomy shortly after the biopsy. tumors were negative (10 tumors that had weak membranous staining were included in the negative group). A correlation was observed between tumor stage and grade, as expected, with a P value Ͻ 0.0001 (Table  2) . Patients with well differentiated tumors (Grade 1) presented more often at an earlier stage (pTa; 66%), and patients with poorly differentiated tumors (Grade 3) presented more often at a more advanced stage (pT2; 84%). Patients with moderately differentiated tumors (Grade 2) presented more often as pT1 tumors (63%).
The relation between CD9 expression and tumor stage and grade is noted in Table 3 ( Figs. 2A,B, 3A,B) . A significant association between CD9 expression and tumor stage was noted (P Ͻ 0.0001). Among CD9 positive tumors, 60% were pTa, 32% were pT1, and 7% were pT2. Among CD9 negative tumors, 3% were pTa, 27% were pT1, and 70% were pT2. Reduced expression of CD9 was seen in 20%, 46%, and 32% of pTa, pT1, and pT2 tumors, respectively. There also was a significant association between CD9 expression and tumor grade (P Ͻ 0.0001) ( Table 3) . Among CD9 positive tumors, 50%, 43%, and 6.7% were Grade 1, Grade 2, and Grade 3, respectively. Among CD9 negative tumors, zero tumors were Grade 1, 13.5% of tumors were The relation between CD9 expression and tumor behavior is illustrated in Table 4 . Applying logistic regression, the crude odds ratio associated with positive CD9 expression (which is an estimate of the relative risk of progression vs. tumor regression) amounted to 0.15. This means that patients who had pTa or pT1 tumors with Ͻ 5% CD9 positive cells were 6.72 (1/0.15) times more likely to develop tumor progression (P Յ 0.001; 95% CI, 2.55-17.71) compared with patients who had tumors with Ͼ 50% CD9 expression. Adjusted for age, gender, and grade, the odds ratio is 5.59 (P ϭ 0.005; 95% CI, 1.69 -18.48). Thus, when adjusting for all other variables, aberrant CD9 expression remained a significant predictor of tumor progression (Table 5) .
The Kaplan-Meier curves using the log-rank test were performed to evaluate the time delay to the first recurrence and to the first progression in patients with pTa and pT1 tumors (Figs. 4, 5) . The Kaplan-Meier curves showed that CD9 expression was not signifi- cant in predicting recurrence free survival in patients with pTa or pT1 tumors (P ϭ 0.33). However, positive CD9 expression was associated significantly with slower disease progression in patients with pTa and pT1 tumors (P Ͻ 0.001). Thus, patients who had tumors with positive CD9 expression were more likely to have a longer time to progression compared with patients who had tumors with negative and reduced CD9 expression.
A multivariate Cox regression analysis is shown in Table 6 . The Cox regression model revealed that only the pathologic grade was statistically significant (P ϭ 0.003) in predicting recurrence. Thus, only pathologic grade appeared to be an independent factor for predicting tumor recurrence, and CD9 did not add any information. The same Cox regression model applied to study the predictors of tumor progression revealed that pathologic grade, stage, and CD9 expression (positive vs. negative) were statistically significant (P Ͻ 0.0001). Most important, when simultaneously adjusting for all of the other variables, only CD9 expression maintained its independent prognostic value for predicting tumor progression (P ϭ 0.007), whereas pathologic grade and stage failed to maintain any value.
DISCUSSION
The current study used a large data base of 320 patients to address two issues. To address the first issue (i.e., the relation of CD9 expression to tumor grade and stage), all 320 patients were included. However, to address the second issue (i.e., the relation of CD9 to tumor behavior in SPTs), data from patients with pT2 tumors were not relevant and were not included. Thus, the study included 202 patients with SPTs who had long-term follow-up (range, 12-240 months). This long follow-up provided an accurate and complete understanding of the behavior of these repeatedly recurrent superficial tumors.
This study showed a strong association of aberrant CD9 expression (reduced or negative) with two major, well established predictive factors of tumor behavior: tumor grade and stage. Low-grade tumors, which often are positive for CD9 expression, are less likely to become more aggressive and to invade the muscularis propria. Consequently, high-grade tumors, which usually are negative for CD9 expression, are more likely to progress and invade.
With regard to tumor behavior, only the extreme values of CD9 were important in predicting tumor progression in patients with SPTs. That is, patients who had pTa and pT1 tumors with an absence of CD9 expression were more likely to progress compared with patients who had tumors with positive CD9 expression. Thus, CD9 expression may be used as an additional marker for predicting disease progression in both pTa and pT1 superficial tumors. In patients with these tumors, progression is a life-threatening issue and is worth identifying as such, so that patients can be managed more closely and may be treated more aggressively. In this context, CD9 may be considered a useful tool for identifying patients who are at risk for disease progression and for whom closer follow-up is required. When other variables, such as age, gender, grade, stage, and CD9 expression, were taken into consideration, CD9 expression appeared to be a powerful, independent prognostic factor regarding progression free survival. Thus, it appears that CD9 expression was superior to tumor grade and stage in predicting progression free survival. For the probability of recurrence free survival in patients with SPTs, only tumor grade proved to be an independent predictor, whereas CD9 expression did not seem to have any prognostic value. Although BCG therapy may have an impact on tumor recurrence, there is no evidence that it has an effect on long-term progression in patients with SPTs. 25 Thus, it is unlikely that BCG was a source of bias in the current study.
This study also showed a strong correlation between tumor grade and depth of invasion. The majority of noninvasive tumors were well differentiated, and the invasive tumors were poorly differentiated. Conversely, pT1 tumors were mostly moderately differentiated. 5 These findings are in accordance with data from the literature. 26 -29 Clinical studies have demonstrated the prognostic value of CD9 in patients with adenocarcinoma of the colon, lung, pancreas, and breast and patients with squamous cell carcinoma of the esophagus and oral cavity. 16 -22 Miyake et al. 16 evaluated the value of CD9 expression in breast carcinoma for predicting prognosis after surgery. In their study, those authors concluded that, in addition to hormone receptor status and lymph node status, positive expression of CD9 by tumor cells was correlated with disease free survival and, thus, that testing for CD9 expression could identify patients who may have a high risk for recurrence. Along the same lines, Huang et al. 17 showed that patients with breast carcinoma who had negative CD9 expression had shorter disease free survival and a shorter 5-year survival rate compared with patients who had positive CD9 expression. Higashiyama et al. 20 found that positive expression of CD9 was an independent prognostic factor for disease free survival in patients with adenocarcinoma of the lung. Uchida et al. 21 found that reduction or absence of CD9 expression correlated well with lymph node metastasis and may predict prognosis in patients with esophageal squamous cell carcinoma. Kusukawa et al. 22 found that loss of CD9 staining was associated with a high incidence of lymph node metastasis and a poorer prognosis in patients with squamous cell carcinoma of the oral cavity. However, the value of CD9 in patients with urothelial bladder carcinoma has not been documented to date, and the current study is the first to do so. The lack of studies in the literature on the exact topic discussed in our study make the comparison of our data with others difficult. In addition, because superficial bladder tumors and solid tumors, such as tumors of the colon, breast, and lung, have different behavior (for example, the former are prone to recur and progress, and the latter disseminate to lymph node and distant metastasis, leading to death), a comparison of our data with data from patients with these forms of cancer would not be valid. The next step will be to evaluate CD9 expression in muscular invasive tumors (pT2) and its relation to lymph node metastasis and survival. In the current study, aberrant expression of CD9 was found to be associated significantly with tumor grade and depth of invasion in urothelial bladder carcinoma. In addition, CD9 expression appears to be an independent factor for predicting tumor progression. Thus, IHC assessment of CD9 expression in superficial tumors (pTa and pT1) may become a promising tool for predicting tumor behavior in patients with superficial bladder carcinoma. By selecting those with tumors that are likely to progress, patients may benefit from more efficient management earlier in the course of their disease. 
